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Over the last two decades, arsenic trioxide (ATO) has been used
successfully for the treatment of many types of hematologic malig-
nancies [1–4]. Recent clinical trials have also demonstrated prom-
ising results with ATO on a variety of solid tumors [5–8]. To date,
various mechanisms of ATO have been investigated [9], such as
those involved in the stimulation of differentiation or the induction
of apoptosis. Recently, there is emerging evidence that autophagy
plays an important role in ATO-induced toxicity [10–12]. However,
the exact molecular mechanisms involved in ATO-induced autoph-
agy require further investigation.
Cellular FLIP (FLICE-like inhibitory protein), which is critical for
protection against death receptor-mediated cell apoptosis [13], is
overexpressed in many tissues, mainly in two major isoforms, FLIP
long (FLIPL) and FLIP short (FLIPS). FLIP has been reported to notchemical Societies. Published by E
ine; FLIPL, FLICE-like inhibi-
hort; Cbl-b, casitas B-lineage
dhesion kinase
Medical Oncology, The First
anjing Street, Heping District,
iu), qu_xiujuan@hotmail.comonly possess anti-apoptotic activity but also serve as an anti-
autophagy molecule [14–15]. A previous study suggested that
ATO induced apoptosis via down-regulation of FLIP in myelodys-
plastic syndromes and myeloid leukemia cells [16]. However,
whether FLIP is involved in ATO-induced autophagy remains
unclear.
The casitas B-lineage lymphoma (Cbl) family of E3 ubiquitin li-
gases plays a key role in the determination of ubiquitinated sub-
strate proteins and in regulating cell function [17–20]. In tumor
necrosis factor (TNF)-treated mouse macrophage cells, c-Cbl is in-
volved in ubiquitination and degradation of FLIPS [21]. c-Cbl also
degrades active Src for autophagy in focal adhesion kinase (FAK)-
deﬁcient mouse squamous carcinoma cells [22]. Our prior observa-
tions indicated that ATO could up-regulate the expression of Cbl-b,
another Cbl family member, in both acute promyelocytic leukemia
and gastric cancer cells [23]. However, the function of Cbl-b up-
regulated by ATO is not fully understood.
In the present study, we demonstrated that degradation of FLIPL
was associated with ATO-induced protective autophagy in hema-
tologic and solid tumor cells. Most notably, the ubiquitin E3 ligase
Cbl-b interacted with FLIPL and triggered proteasomal degradation
of FLIPL, which facilitated ATO-induced autophagy. These observa-
tions suggest that FLIPL is a critical regulator of ATO-induced
autophagy in leukemic K562 and gastric cancer cells.lsevier B.V. All rights reserved.
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2.1. Cell culture
Human chronic myelogenous leukemic cell line (K562), human
T lymphoma cell line (Jurkat), human breast cancer cell line (MCF-
7) and human gastric cancer cell line (MGC803) were obtained
from the Type Culture Collection of the Chinese Academy of Sci-
ences (Shanghai, China). All cells were cultured in RPMI-1640 med-
ium (Gibco) containing 10% heat-inactivated fetal bovine serum
(FBS), penicillin (100 U/ml) and streptomycin (100 mg/ml) at
37 C under an atmosphere of 95% air and 5% CO2.Table 1
IC50 values obtained following treatment with ATO in K562, Jurkat, MCF-7 and
MGC803 cell lines. Data are means ± SDs.
Cells IC50/24 h(lM) IC50/24 h(lM)
K562 4.59 ± 1.53 2.82 ± 0.96
Jurkat 5.92 ± 1.39 3.68 ± 1.01
MCF-7 49.76 ± 8.34 20.48 ± 5.66
MGC803 59.33 ± 7.90 26.91 ± 4.432.2. Reagents and antibodies
Arsenic trioxide (ATO) and chloroquine (CQ) were purchased
from Sigma–Aldrich (St. Louis, MO, USA). PS341 (Bortezomib) was
purchased from Millenium Pharmaceuticals Inc. (Cambridge, MA,
USA). Anti-Cbl-b, anti-actin, anti-p62, anti-Beclin 1, anti-PARP and
anti-FLIP antibodies were purchased from Santa Cruz Biotechnol-
ogy (USA). Anti-LC3 antibody was purchased from Novus Biological
(Littleton, CO, USA) and anti-phosphotyrosine 4G10 was purchased
from Upstate Biotechnology (Lake Placid, NY).
2.3. Cell viability assay, ﬂow cytometry and Western blot analysis
These experiments were performed as described previously
[23].
2.4. Transmission electron microscopy
Cells were treated and collected by trypsinization, then ﬁxed
with 2.5% phosphate-buffered gluteraldehyde, postﬁxed in 1%
phosphate-buffered osmium tetroxide. Cells were then embedded,
sectioned, double stained with uranyl acetate and lead citrate, and
analyzed using a JEM-1200EX transmission electron microscope
(JEOL, Japan).
2.5. Immunoprecipitation assay
Cells were collected and lysed in an NP40 buffer supplemented
with complete protease inhibitor cocktail (Roche). After pre-clear-
ingwith protein A/G agarose beads for 2 h at 4 C, whole-cell lysates
were used for immunoprecipitation with the indicated antibodies.
Generally, 1–4 lg of the commercial antibody or immunoglobu-
lin-G (Santa Cruz, CA, USA) was added to 1 ml of the cell lysate
and incubated at 4 C for 8–12 h. After adding protein A/G agarose
beads, incubation was continued for an additional 1 h. The immu-
noprecipitates were then washed extensively with a lysis buffer
and eluted by boiling them with an SDS loading buffer for 5 min.
2.6. Transfections of plasmid constructs
The experiment was performed as described previously [24].
2.7. Small interfering RNA transfections
Cells were seeded at a density of 3  105 cells/well in 6-well
plates. After 24 h, cells were transfected with small interfering
RNA (siRNA) using Lipofectamine 2000 reagent according to the
manufacturer’s protocols. The FLIPL siRNA sequence used was:
AAG GAA CAG CTT GGC GCT CAA. The FLIPS siRNA sequence used
was: AAC ATG GAA CTG CCT CTA CTT. The Beclin 1 siRNA sequence
used was: CAG TTT GGC ACA ATC AAT ATT. The Cbl-b siRNA
sequence used was: AAA GTG GTA AGA CTG TGC CAA. The Ctrlsequence used was: AAT TCT CCG AAC GTG TCA CGT. FLIPL, FLIPS,
Beclin 1, Cbl-b and Ctrl siRNAs were produced from Genechem
Co. (Shanghai, China). Gene silencing effect was veriﬁed by
Immunoblotting.
2.8. Statistical analysis
All the presented data were conﬁrmed in at least three indepen-
dent experiments, and are expressed as the mean ± SD. Statistical
comparisons were made by Student’s t test. P < 0.05 was consid-
ered statistically signiﬁcant.
3. Results
3.1. ATO affects cell viability, and induces apoptosis and protective
autophagy in malignant hematologic and solid tumor cell lines
K562, Jurkat, MCF-7 and MGC803 cell lines were treated with
different concentrations of ATO for 24 or 48 h, and viability was
evaluated. The IC50 values of ATO at 24 h in K562, Jurkat, MCF-7
and MGC803 cells were 4.59 ± 1.53 lM, 5.92 ± 1.39 lM,
49.76 ± 8.34 lM, and 59.33 ± 7.90 lM, respectively (Table 1). To
investigate whether ATO is a direct activator of autophagic ﬂux,
we detected microtubule-associated protein light chain 3 (LC3)
(LC3-I/LC3-II) by immunoblot analysis. As shown in Fig.1A, treat-
ment with ATO signiﬁcantly induced a time-dependent increase
in the expression of both LC3-I and LC3-II in K562, Jurkat, MCF-7
and MGC803 cells accompanied by PARP cleavages. It has been re-
ported that the sequestosome 1 (p62) protein has LC3 binding do-
mains for serving as a selective substrate of autophagy [25].
Consistent with increased autophagic ﬂux following treatment
with ATO, there was a time-dependent decrease in the level of
p62 by immunoblotting (Fig. 1A). Furthermore, ATO-induced
autophagy was conﬁrmed by transmission electron microscopy
(formation of autophagosomes) in K562 andMGC803 cells (Supple-
mentary Fig. S1). Because autophagy can result in both cell survival
and death, we next determined whether ATO-induced autophagy
was protective or pro-apoptotic. Treatment of K562 cells with
either ATO, CQ (an inhibitor of autophagy that stops autophagy at
the late phase), or a combination of ATO and CQ for 24 h revealed
that combined treatment with ATO and CQ decreased cell viability,
and increased apoptotic cell death compared to ATO or CQ treat-
ment alone. Similar results were also observed in MGC803 cells
(Fig. 1B and C). To conﬁrm the effect of autophagy inhibition by
the pharmacologic agent CQ on ATO-induced apoptosis, an RNA
interference approach was used to suppress the expression of Be-
clin 1, which is required for the initiation of the formation of
autophagasome [26]. Reduced cell viability in MGC803 cells was
observed with knockdown of Beclin 1 (Fig. 1D). These data indi-
cated that blockage of autophagy enhanced the antitumor effect
of ATO in K562 and MGC803 cells.
3.2. FLIPL is involved in ATO-induced autophagy
To investigate whether FLIP expression was associated with
ATO-induced autophagy, K562, Jurkat, MCF-7 and MGC803 cells
were treated with ATO. Results showed that the levels of FLIPL pro-
Fig. 1. ATO induced apoptosis and protective autophagy in malignant hematologic and solid tumor cell lines. (A) K562, Jurkat, MCF-7 and MGC803 cells were incubated with
ATO for the indicated times. PARP cleavage and LC3 expression were analyzed by immunoblot. (B) K562 cells and MGC803 cells were treated with either ATO or 20 lM CQ, or
a combination of ATO and CQ for 24 h, and cell viability was measured by the trypan blue exclusion assay or MTT assay. Differences between treatment groups were
determined using Student’s t test and by calculating subsequent P values. ⁄P < 0.05. (C) Cell apoptosis was determined by ﬂow cytometry. (D) MGC803 cells were transiently
transfected with Beclin 1-speciﬁc siRNA for 48 h, followed by 20 lM ATO for 24 h, and cell viability was measured by MTT assay. ⁄P < 0.05 vs. cells transfected with control
siRNA.
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lines, but the levels of FLIPS in solid tumor cells were not consistent
with leukemia cells (Fig. 2A). We therefore investigated the effect
of FLIPL on autophagy. To assess the effect of FLIPL on autophagy,
FLIPL-targeted siRNA was transfected in MGC803 cells. Suppression
of FLIPL induced signiﬁcant levels of PARP cleavage and LC3-II
expression (Fig. 2B), indicating activation of apoptosis and autoph-
agy. Furthermore, speciﬁc down-regulation of FLIPL enhanced ATO-
induced autophagy in MGC803 cells as indicated by the up-regula-
tion of LC3-II (Fig. 2C). The result was further conﬁrmed by trans-
mission electron microscopy (Supplementary Fig. S2). However,
ATO-induced autophagy in MGC803 cells remained no changes in
down-regulation of FLIPS (Fig. 2D), suggest that FLIPL plays more
important role in the regulation of ATO-induced autophagy.
3.3. Degradation of FLIPL protein by ATO is mediated through the
ubiquitin–proteasome pathway
To explore whether FLIPL was regulated by the ubiquitin–pro-
teasome pathway, the proteasome inhibitor PS341 was used to in-
hibit the function of the proteasomal pathway. In ATO-treated
K562 cells, pretreatment with PS341 could effectively prevent
FLIPL degradation (Fig. 3A left). A similar effect was observed in
MGC803 cells (Fig. 3A right). Because phosphorylation of tyrosine
residues could serve as a signal for ubiquitination [27], phosphor-
ylation of FLIPL was examined in ATO-treated K562 and MGC803
cells. Compared to the control, the results revealed an increase in
phosphorylated FLIPL at 3 h in K562 cells (Fig.3B left) or at 1 h in
MGC803 cells (Fig. 3B right). Next, ATO-induced ubiquitination of
the FLIPL protein was investigated. Consistent with the fact that
ubiquitination precedes proteasomal degradation, polyubiquitinat-ed FLIPL was evident within 3 h in K562 cells after ATO treatment
(Fig. 3C left). A similar effect was also obtained in MGC803 cells
after treatment of ATO within 1 h (Fig. 3C right). These ﬁndings
suggested that FLIPL was ubiquitinated during ATO-treated K562
and MGC803 cells.
3.4. Cbl-b is involved in the ubiquitination of FLIPL
To determine whether the E3 ubiquitin ligase Cbl-b was in-
volved in ubiquitination of FLIPL, K562 and MGC803 cells were
treated with ATO, and the level of Cbl-b protein was detected.
Immunoblotting showed that the expression of Cbl-b increased
in a time-dependent manner (Fig. 4A). Furthermore, an interaction
between Cbl-b and FLIPL was found in ATO-treated K562 and
MGC803 cells (Fig. 4B). To characterize whether FLIPL was ubiqui-
tinated by Cbl-b, previously established MGC803 cells stably trans-
fected with the shRNA plasmid of Cbl-b [24] were used for further
experiments (Fig. 4C). Knockdown of Cbl-b signiﬁcantly inhibited
ATO-dependent ubiquitination of FLIPL (Fig. 4D). These results indi-
cated that Cbl-b was required for ATO-induced ubiquitination of
FLIPL in K562 and MGC803 cells.
3.5. Cbl-b is involved in ATO-induced human gastric cancer cell
autophagy
Next, to characterize the effect of Cbl-b on ATO-induced
autophagy, Cbl-b speciﬁc shRNA was used to silence Cbl-b expres-
sion in MGC803 cells. Speciﬁc silenced Cbl-b expression induced
the down-regulation of LC3-II levels and the up-regulation of FLIP
protein (Fig. 5A). Moreover, shRNA-mediated knockdown of Cbl-b
effectively suppressed autophagy induced by ATO or starvation,
Fig. 2. FLIPL is involved in ATO-induced autophagy. (A) K562, Jurkat, MCF-7 and MGC803 cells were incubated with ATO for the indicated times, immunoblot analysis of FLIPL
and FLIPS expression in all cell lines. (B) After transiently transfection with FLIPL-speciﬁc siRNA for 48 h in MGC803 Cells, the expression of FLIPL, FLIPS, LC3 and PARP cleavage
were analyzed by immunoblot. (C) MGC803 Cells were transiently transfected with FLIPL-speciﬁc siRNA for 48 h, followed by 20 lM ATO for 12 h. LC3 expression was
analyzed by immunoblot. (D) MGC803 Cells were transiently transfected with FLIPS-speciﬁc siRNA for 48 h, followed by 20 lM ATO for 12 h. LC3 expression and PARP
cleavage were analyzed by immunoblot.
Fig. 3. Degradation of FLIPL protein by ATO is mediated through the ubiquitin–proteasome pathway. (A) K562 and MGC803 cells were without pretreated or pretreated for
12 h with 5 nM PS341, and then incubated with ATO for indicated times, FLIPL was analyzed by immunoblot. (B) K562 and MGC803 cells were incubated with ATO for
indicated times, FLIPL was immunoprecipitated and then the phosphorylated tyrosine was analyzed by immunoblot. (C) K562 and MGC803 cells were pretreated for 12 h with
5 nM PS341, and then incubated with ATO, FLIPL was immunoprecipitated and the ubiquitin was analyzed by immunoblot. (Ub) n-FLIPL, polyubiquitinated FLIPL. The non-
speciﬁc beads was included in immunoprecipitation step as negative control.
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microscopy studies also showed a decrease in the number of ATO-
induced autophagic vacuoles in Cbl-b silencing MGC803 cells when
compared to non-silencing control cells (Supplementary Fig. S3).
Furthermore, the inhibition of autophagy induced by Cbl-b deple-tion was reverted by knockdown of FLIPL in Cbl-b silencing
MGC803 cells (Fig. 5D). Moreover, siRNA-mediated knockdown of
Cbl-b in K562 cells also suppressed ATO-induced autophagy
(Fig. 5E). These observations collectively indicated that Cbl-b might
enhance ATO-induced autophagy in K562 and MGC803 cells.
Fig. 4. Ubiquitination of FLIPL requires Cbl-b. (A) K562 and MGC803 cells were treated with ATO for the indicated times, Cbl-b was analyzed by immunoblot. (B) K562 and
MGC803 cells were treated with ATO for 3 h before immunoprecipitation with anti-FLIPL antibody, Cbl-b was analyzed by immunoblot. (C) Cell viability and Cbl-b expression
were analyzed in MGC803 Cells stable transfected with control or Cbl-b-speciﬁc shRNA. (D) The Cells were pretreated for 12 h with 5 nM PS341 and then for indicated times
with 20 lM ATO, FLIP was immunoprecipitated and the ubiquitin was analyzed by immunoblot.
Fig. 5. Cbl-b is involved in ATO-induced human gastric cancer cell autophagy. (A) Immunoblot analysis of FLIPL and LC3 expression in MGC803 Cells stable transfected with
control or Cbl-b-speciﬁc shRNA. (B) The cells were treated with 20 lM ATO for 6 h or 12 h, LC3 expression was analyzed by immunoblot. (C) The cells were treated with
Hank’s balanced salt solution for 12 h, LC3 expression was analyzed by immunoblot. HBSS, Hank’s balanced salt solution. (D) MGC803 Cells stable transfected with Cbl-b-
speciﬁc shRNA were transiently transfected with FLIPL-speciﬁc siRNA for 48 h, followed by 20 lM ATO for 12 h, LC3 expression was analyzed by immunoblot. (E) K562 Cells
were transiently transfected with Cbl-b-speciﬁc siRNA for 48 h, followed by 5 lM ATO for 12 h, LC3 expression was analyzed by immunoblot.
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Autophagy is a cellular catabolic degradation response to nutrient
starvation or metabolic stress. Previous reports have shown that
autophagy is activated by some anti-tumor drugs that induce apopto-
sis [28]. But, whether autophagy is a death-induced mechanism or a
protective effort for cellular survival after chemotherapy is still con-troversial [29]. As reported recently, ATO induced not only apoptosis
but also autophagy in leukemia cells [11]. It is important to under-
stand in detail the signaling pathways involved in this process. ATO
was suggested to induce autophagic cell death in acute myelogenous
leukemia and malignant glioma cells [11,30]. However, in our obser-
vations, ATO was observed to induce protective autophagy and not
autophagic cell death in K562 and MGC803 cells. Therefore, the
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types of malignant cells. In our study, we showed that treatment with
ATO increased both the expression of LC3-I and the expression of LC3-
II in K562, Jurkat, MCF-7 and MGC803 cells. These phenomena have
also been seen in the other author’s studies on the effect of ATO
[12,31–32]. However, the exact mechanism is unclear.
FLIP is a key inhibitor of death receptor signaling. Micheau et al.
[33] reported that FLIPL (but not FLIPS) blocks caspase-8-mediated
apoptosis. In our study, FLIPL was strongly down-regulated by
ATO in a time-dependent manner in all cell lines. These ﬁndings
conﬁrmed that down-regulation of FLIPL by ATO is not a cell line
speciﬁc effect. Several studies reported that down-regulation of
FLIPL could induce spontaneous apoptosis [34–35]. Our results have
shown for the ﬁrst time that FLIPL-targeted siRNA induced not only
spontaneous apoptosis but also spontaneous autophagy inMGC803
cells. Lee et al. [15] demonstrated that in NIH3T3 cells, FLIP sup-
pressed autophagy by regulating the autophagy signal transduction
pathway in autophagosome elongation. Our results also found that
speciﬁc down-regulation of FLIPL signiﬁcantly enhanced ATO-in-
duced autophagy in MGC803 cell lines. Collectively, these results
demonstrate that FLIPL is a critical regulator of both apoptosis and
autophagy in ATO-treated K562 and MGC803 cells.
Data have emerged that post-transcriptional regulation of pro-
teins plays an important role in regulating cell signal pathways.
For example, ubiquitination of FLIPL by the ubiquitin E3 ligase Itch
has been reported to control TNF-induced cell death [36]. TNF-
dependent ubiquitination of FLIPS is regulated by c-Cbl inMycobac-
terium tuberculosis-inducedmacrophage apoptosis [21]. Cbl-b is the
secondmember of the Cbl family of proteins, and is essential for the
negative regulation of T-cell activation, growth factor receptor and
non-receptor-type tyrosine kinase signaling [37–39]. Here we dem-
onstrated that ATO treatment led to up-regulation of Cbl-b and deg-
radation of FLIPL proteins in both K562 and MGC803 cells. Further
experiments indicated that Cbl-b interacted with FLIPL in K562
andMGC803 cells. Knockdown of Cbl-b signiﬁcantly inhibited ubiq-
uitination of FLIPL, suggesting the involvement of Cbl-b in the reg-
ulation of FLIPL turnover. A recent study demonstrated that
Autophagic regulation of Src was mediated by c-Cbl when the
Src/FAK pathway is disrupted [22]. In our study, ATO-dependent
activation of autophagy was considerably blocked by knockdown
of Cbl-b, which was mediated via regulating degradation of FLIPL.
This study is the ﬁrst to report that Cbl-b is essential for ATO-in-
duced autophagy in K562 and MGC803 cells.
Takentogether, thepresentobservations indicate thatATO-induced
autophagy inK562andMGC803cells ismediatedthroughproteasomal
degradationof FLIPL. This is theﬁrst study to showthatFLIPL is involved
inATO-inducedprotectiveautophagy.Furthermore, theE3ubiquitin li-
gase Cbl-b is a key participant of autophagy induced by ATO, which
facilitates FLIPL degradation. These observations collectively suggest
that FLIPL is a critical regulator of ATO-induced autophagy in K562
and MGC803 cells, and that a combination of ATO and FLIPL targeted
agents may have considerable therapeutic beneﬁt.
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